home.social

#ablbio — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #ablbio, aggregated by home.social.

  1. Yonhap Infomax News @[email protected] ·

    March FTSE index rebalancing set for March 20 expected to drive significant inflows into mid-cap promoted stocks, with APR, ABL Bio, Rainbow Robotics, and ISU Petasys anticipated to attract combined net buying of over 600 billion won as they upgrade from small-cap status
    #YonhapInfomax #FTSERebalancing #APR #ABLBio #MidCapPromotion #NetBuyingDemand #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ftserebalancing #apr #ablbio #midcappromotion #netbuyingdemand
  2. Yonhap Infomax News @[email protected] ·

    March FTSE index rebalancing set for March 20 expected to drive significant inflows into mid-cap promoted stocks, with APR, ABL Bio, Rainbow Robotics, and ISU Petasys anticipated to attract combined net buying of over 600 billion won as they upgrade from small-cap status
    #YonhapInfomax #FTSERebalancing #APR #ABLBio #MidCapPromotion #NetBuyingDemand #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ftserebalancing #apr #ablbio #midcappromotion #netbuyingdemand
  3. Yonhap Infomax News @[email protected] ·

    March FTSE index rebalancing set for March 20 expected to drive significant inflows into mid-cap promoted stocks, with APR, ABL Bio, Rainbow Robotics, and ISU Petasys anticipated to attract combined net buying of over 600 billion won as they upgrade from small-cap status
    #YonhapInfomax #FTSERebalancing #APR #ABLBio #MidCapPromotion #NetBuyingDemand #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  4. Yonhap Infomax News @[email protected] ·

    March FTSE index rebalancing set for March 20 expected to drive significant inflows into mid-cap promoted stocks, with APR, ABL Bio, Rainbow Robotics, and ISU Petasys anticipated to attract combined net buying of over 600 billion won as they upgrade from small-cap status
    #YonhapInfomax #FTSERebalancing #APR #ABLBio #MidCapPromotion #NetBuyingDemand #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ftserebalancing #apr #ablbio #midcappromotion #netbuyingdemand
  5. Yonhap Infomax News @[email protected] ·

    ABL Bio CEO Lee Sang-hoon announced at the JP Morgan Healthcare Conference that the company expects to secure new global partnerships beyond GSK, Eli Lilly, and Sanofi, following multi-trillion won licensing deals and ongoing clinical progress.
    #YonhapInfomax #ABLBio #GSK #EliLilly #LicensingDeal #ClinicalProgress #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #gsk #elililly #licensingdeal #clinicalprogress
  6. Yonhap Infomax News @[email protected] ·

    ABL Bio CEO Lee Sang-hoon announced at the JP Morgan Healthcare Conference that the company expects to secure new global partnerships beyond GSK, Eli Lilly, and Sanofi, following multi-trillion won licensing deals and ongoing clinical progress.
    #YonhapInfomax #ABLBio #GSK #EliLilly #LicensingDeal #ClinicalProgress #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #gsk #elililly #licensingdeal #clinicalprogress
  7. Yonhap Infomax News @[email protected] ·

    ABL Bio CEO Lee Sang-hoon announced at the JP Morgan Healthcare Conference that the company expects to secure new global partnerships beyond GSK, Eli Lilly, and Sanofi, following multi-trillion won licensing deals and ongoing clinical progress.
    #YonhapInfomax #ABLBio #GSK #EliLilly #LicensingDeal #ClinicalProgress #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  8. Yonhap Infomax News @[email protected] ·

    ABL Bio CEO Lee Sang-hoon announced at the JP Morgan Healthcare Conference that the company expects to secure new global partnerships beyond GSK, Eli Lilly, and Sanofi, following multi-trillion won licensing deals and ongoing clinical progress.
    #YonhapInfomax #ABLBio #GSK #EliLilly #LicensingDeal #ClinicalProgress #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #gsk #elililly #licensingdeal #clinicalprogress
  9. Yonhap Infomax News @[email protected] ·

    Foreign investors are increasingly buying South Korean stocks expected to join the MSCI Korea Index, with Isu Petasys and ABL Bio emerging as top candidates for the February 2025 review, driven by strong foreign inflows and notable share price gains.
    #YonhapInfomax #MSCI #ForeignInvestors #IsuPetasys #ABLBio #IndexInclusion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #msci #foreigninvestors #isupetasys #ablbio #indexinclusion
  10. Yonhap Infomax News @[email protected] ·

    Foreign investors are increasingly buying South Korean stocks expected to join the MSCI Korea Index, with Isu Petasys and ABL Bio emerging as top candidates for the February 2025 review, driven by strong foreign inflows and notable share price gains.
    #YonhapInfomax #MSCI #ForeignInvestors #IsuPetasys #ABLBio #IndexInclusion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #msci #foreigninvestors #isupetasys #ablbio #indexinclusion
  11. Yonhap Infomax News @[email protected] ·

    Foreign investors are increasingly buying South Korean stocks expected to join the MSCI Korea Index, with Isu Petasys and ABL Bio emerging as top candidates for the February 2025 review, driven by strong foreign inflows and notable share price gains.
    #YonhapInfomax #MSCI #ForeignInvestors #IsuPetasys #ABLBio #IndexInclusion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  12. Yonhap Infomax News @[email protected] ·

    Foreign investors are increasingly buying South Korean stocks expected to join the MSCI Korea Index, with Isu Petasys and ABL Bio emerging as top candidates for the February 2025 review, driven by strong foreign inflows and notable share price gains.
    #YonhapInfomax #MSCI #ForeignInvestors #IsuPetasys #ABLBio #IndexInclusion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #msci #foreigninvestors #isupetasys #ablbio #indexinclusion
  13. Ireland @[email protected] ·

    europesays.com/ie/186411/ Deal With Eli Lilly Propels Founder Of Korean Biotech Firm Into Billionaire Ranks #AbbVie #ABLBio #BiotechStocks #Business #Éire #EliLilly #EliLillyZepbound #IE #Ireland #KoreaBiotech #Mounjaro #NovoNordisk #ozempic #pfizer

    #pfizer #ozempic #novonordisk #mounjaro #koreabiotech #ireland
  14. Yonhap Infomax News @[email protected] ·

    ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
    #YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #elililly #paidincapitalincrease #technologytransfer #adcplatform
  15. Yonhap Infomax News @[email protected] ·

    ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
    #YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #elililly #paidincapitalincrease #technologytransfer #adcplatform
  16. Yonhap Infomax News @[email protected] ·

    ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
    #YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  17. Yonhap Infomax News @[email protected] ·

    ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
    #YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #elililly #paidincapitalincrease #technologytransfer #adcplatform
  18. Yonhap Infomax News @[email protected] ·

    ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
    #YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #glaxosmithkline #technologytransfer #grabodyb #biotechindustry
  19. Yonhap Infomax News @[email protected] ·

    ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
    #YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #glaxosmithkline #technologytransfer #grabodyb #biotechindustry
  20. Yonhap Infomax News @[email protected] ·

    ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
    #YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #glaxosmithkline #technologytransfer #grabodyb #biotechindustry
  21. Yonhap Infomax News @[email protected] ·

    ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
    #YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  22. Yonhap Infomax News @[email protected] ·

    ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
    #YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #ablbio #glaxosmithkline #technologytransfer #grabodyb #biotechindustry